Bill117th CongressFiled Jun 30, 2021Health
H.R. 4278
To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.
Bill journey · stage 2 of 5
Under committee review
FiledFiled
CommitteeComm.
PassedFloor
Both ChambersBoth
Became LawLaw
What it doesSummary introduced in house (Jun 30, 2021)
This bill requires the Government Accountability Office to study and report on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers.
What just happenedJul 1, 2021
Referred to the Subcommittee on Health.
Who’s behind it
Rep. Murphy, Gregory [R-NC-3](R-NC)Sponsor
1 cosponsor1 R
1cosponsors1committees4actions
- Introduced in HouseJun 30, 2021
- Jul 1, 2021Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jun 30, 2021IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Jun 30, 2021IntroReferralIntro-H
Introduced in House
- Jun 30, 2021IntroReferral1000
Introduced in House